Abstract
The aim of this study was to analyze the survival predictions obtained from an online nomogram, originally developed in two US patient cohorts with metastatic hormone-sensitive prostate cancer, because clinical practice and survival outcomes may vary on an international level. A retrospective single-institution study of 197 patients, managed according to Norwegian guidelines, was performed. Model-predicted survival was assessed online and compared to observed survival. The median overall survival was 32.7 months. The nomogram predicted 3-year survival probabilities of 3-72% and 5-year probabilities of 0-54% in individual patients. Regarding 3-year prediction, the median was 47% (observed 3-year survival: 45%). The corresponding 5-year figures were 30% (nomogram) and 25% (observed). In univariate Cox regression, predicted 3-year and 5-year likelihood of survival were associated with observed survival of the study population (both p<0.001). The survival predictions from the US nomogram were correlated with observed survival in this Norwegian validation study.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
